RCEL AVITA Medical
Price Chart
Executive Summary
AVITA Medical reported Q1 2026 EPS of -$0.35, beating consensus by 14.2%. Revenue was not disclosed in this brief release, which primarily serves to invite shareholders to an investor webinar. The EPS beat suggests better-than-expected cost control, but the absence of revenue details tempers enthusiasm.
Actionable Insight
The EPS beat is a positive surprise, but the lack of revenue disclosure and forward guidance limits conviction. Await the webinar for comprehensive financial details; consider a wait-and-see approach before initiating a position.
Key Facts
- Q1 2026 EPS of -$0.35 vs consensus -$0.41 (14.2% beat)
- Revenue not disclosed in the press release
- Company will host an investor webinar on May 20, 2026 to discuss results
Financial Impact
EPS beat of $0.06 per share, or 14.2% above consensus
Risk Factors
- No revenue data or guidance provided
- Ongoing net losses and small market cap ($140M) increase volatility
- Historical stock performance has been weak after positive events
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296271 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 17, 2026
23d ago
|
Press Release
| $4.19 $4.25 | ▲ +1.43% | ▼ −0.19% | $4.12 (−1.67%) |
|
Apr 30, 2026
5w ago
|
Press Release
| $4.32 $4.42 | ▲ +2.31% | ▲ +0.59% | $4.12 (−4.63%) |
|
Apr 23, 2026
6w ago
|
Press Release
| $4.46 $4.32 | ▼ −3.14% | ▼ −4.05% | $4.12 (−7.62%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $5.60 $4.77 | ▼ −14.82% | ▼ −16.22% | $4.12 (−26.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access